1 BTC
=
- USD
iShares Biotechnology ETF
As of May 30, 2026 at 09:15 UTC
Chart
About iShares Biotechnology ETF
No description available.
Market Statistics
Trading Metrics
How to Buy IBB
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy IBB
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesMajor pharmaceutical companies face a patent cliff with $175 billion in annual drug sales losing exclusivity over the next six years, prompting increased M&A activity. Two biotech ETFs—SPDR S&P Biotech (XBI) and iShares Biotechnology (IBB)—offer investors exposure to capitalize on industry volatility and potential winners from consolidation.
Nextech Invest, a Switzerland-based biotech-focused fund, increased its stake in Relay Therapeutics by 855,097 shares (~$6.1 million). The purchase brings Relay to 3.85% of Nextech's portfolio. Relay's stock has surged 197% over the past year, driven by its computational drug discovery platform and clinical-stage pipeline including lead candidates RLY-4008 and RLY-2608.
Vertex Pharmaceuticals shares surged 6.32% in premarket trading after announcing positive Phase 3 RAINIER trial results for its kidney drug povetacicept. The trial met its primary objective with a 52% reduction in urine protein and 49.8% reduction versus placebo. An analyst upgraded the probability of success to 90% ahead of expected FDA approval by year-end.
Boxer Capital Management disclosed a $9.5 million purchase of 1.1 million shares of Tango Therapeutics (TNGX), increasing its stake to 21.09% of the fund's assets. The clinical-stage biotech company, which develops targeted cancer therapies through partnerships including one with Gilead Sciences, has seen its stock surge 426.7% over the past year.
Rye Brook Capital LLC completely liquidated its $3.5 million position in the iShares Biotechnology ETF (IBB), selling 24,270 shares. The complete exit signals a decisive shift in the firm's biotech allocation, potentially reflecting profit-taking concerns after the sector's strong 28% rally over the past year driven by M&A activity, or skepticism about current valuations.
